Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

SELL
$138.54 - $232.0 $8.34 Million - $14 Million
-60,219 Reduced 96.79%
1,999 $400,000
Q2 2022

Aug 11, 2022

BUY
$120.42 - $169.29 $4.6 Million - $6.47 Million
38,222 Added 159.28%
62,218 $9.08 Million
Q1 2022

May 12, 2022

BUY
$127.18 - $173.91 $362,971 - $496,339
2,854 Added 13.5%
23,996 $3.92 Million
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $1.49 Million - $1.96 Million
9,356 Added 79.38%
21,142 $3.59 Million
Q3 2021

Nov 12, 2021

SELL
$169.75 - $207.73 $135,121 - $165,353
-796 Reduced 6.33%
11,786 $2.23 Million
Q2 2021

Aug 10, 2021

SELL
$128.63 - $176.89 $3.27 Million - $4.5 Million
-25,416 Reduced 66.89%
12,582 $2.13 Million
Q1 2021

May 12, 2021

BUY
$126.83 - $175.69 $4.82 Million - $6.68 Million
37,998 New
37,998 $5.37 Million
Q3 2020

Nov 12, 2020

SELL
$121.19 - $165.49 $1.3 Million - $1.77 Million
-10,700 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$104.21 - $156.44 $1.12 Million - $1.67 Million
10,700 New
10,700 $1.59 Million
Q1 2019

May 13, 2019

SELL
$72.76 - $93.45 $144,792 - $185,965
-1,990 Closed
0 $0
Q4 2018

Feb 06, 2019

SELL
$62.67 - $88.33 $1.74 Million - $2.46 Million
-27,794 Reduced 93.32%
1,990 $145,000
Q3 2018

Nov 08, 2018

BUY
$87.52 - $122.67 $1.39 Million - $1.95 Million
15,921 Added 114.85%
29,784 $2.61 Million
Q2 2018

Aug 14, 2018

BUY
$88.31 - $107.8 $1.22 Million - $1.49 Million
13,863 New
13,863 $1.37 Million
Q1 2018

May 11, 2018

SELL
$115.92 - $148.54 $995,405 - $1.28 Million
-8,587 Closed
0 $0
Q4 2017

Feb 09, 2018

SELL
$114.49 - $139.98 $6.89 Million - $8.42 Million
-60,156 Reduced 87.51%
8,587 $1.09 Million
Q3 2017

Nov 15, 2017

BUY
$72.53 - $118.27 $3.02 Million - $4.92 Million
41,601 Added 153.27%
68,743 $8.08 Million
Q2 2017

Aug 14, 2017

BUY
N/A
27,142
27,142 $2.17 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.